Mitochondrial Function and Parkinson’s Disease: From the Perspective of the Electron Transport Chain

Jeng-Lin Li1,2, Tai-Yi Lin3, Po-Lin Chen4, Ting-Ni Guo5, Shu-Yi Huang6, Chun-Hong Chen4, Chin-Hsien Lin1,6 and Chih-Chiang Chan5*

1 Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan, 2 Division of Neurology, Department of Internal Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan County, Taiwan, 3 College of Medicine, National Taiwan University, Taipei, Taiwan, 4 National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan, 5 Graduate Institute of Physiology, National Taiwan University, Taipei, Taiwan, 6 Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

*Correspondence: Chih-Chiang Chan
chancc1@ntu.edu.tw

Parkinson’s disease (PD) is known as a mitochondrial disease. Some even regarded it specifically as a disorder of the complex I of the electron transport chain (ETC). The ETC is fundamental for mitochondrial energy production which is essential for neuronal health. In the past two decades, more than 20 PD-associated genes have been identified. Some are directly involved in mitochondrial functions, such as PRKN, PINK1, and DJ-1. While other PD-associate genes, such as LRRK2, SNCA, and GBA1, regulate lysosomal functions, lipid metabolism, or protein aggregation, some have been shown to indirectly affect the electron transport chain. The recent identification of CHCHD2 and UQCRC1 that are critical for functions of complex IV and complex III, respectively, provide direct evidence that PD is more than just a complex I disorder. Like UQCRC1 in preventing cytochrome c from release, functions of ETC proteins beyond oxidative phosphorylation might also contribute to the pathogenesis of PD.

Keywords: Parkinson’s disease, electron transport chain, mitochondria quality control, mitophagy, apoptosis

INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide with 6.1 million patients globally in 2016 (GBD 2016 Parkinson’s Disease Collaborators, 2018), and up to 12.9 million people estimated to be affected by 2040 (Dorsey and Bloem, 2018). PD is clinically characterized by slowly progressive, levodopa-responsive bradykinesia with either rigidity or resting tremor (Postuma et al., 2015). Dopaminergic neuronal loss and Lewy body formation in the substantia nigra pars compacta are the hallmarks of most PD pathology.

Etiologies of PD are complex. Most individuals with PD are idiopathic. Only 10% of them showed a clear Mendelian inheritance (Hardy et al., 2009), and environmental factors such as pesticides, heavy metals, illicit substances, and diets also contribute (Ball et al., 2019). In 1983 four cases of levodopa-responsive parkinsonism were described after intravenous injection of synthetic heroin containing 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et al., 1983). The neurotoxicity of MPTP results from its oxidized metabolite, 1-methyl-4-phenylpyridine (MPP⁺) (Levitt et al., 1982; Glover et al., 1986), which damages oxidative phosphorylation...
Electron Transport Chain and Parkinson’s Disease

Mitochondria are the powerhouse of eukaryotic cells. This double membrane-bound organelle generates most adenosine triphosphate (ATP) through OXPHOS, processed by ETC embedded in the inner mitochondrial membrane (IMM). ETC is composed of transmembrane complexes I (cI) to V (cV) and two electron carriers, the ubiquinone (i.e., CoQ) and the cytochrome c (cyt c). For ATP production, electrons are transferred from NADH and FADH$_2$ to oxygen via the transport chain, coupled with the generation of a proton gradient across IMM (Zhao et al., 2019; Figure 1).

Complex I (cI) is an NADH-ubiquinone oxidoreductase that pumps four protons into the intermembrane space (IMS) upon each NADH oxidation. cI consists of three modules: the N, Q, and P modules. NADH generated from the tricarboxylic acid cycle delivers its electron to the N module. The electron was then passed to the Q module where the CoQ is reduced to ubiquinol (CoQH$_2$) and induces conformational changes of the P module to allow proton translocation (Giachin et al., 2016). Similarly, cII also transfers electrons to CoQ, but by dehydrogenizing succinate to fumarate, which is a part of the tricarboxylic acid cycle. cII is composed of two subunits: the enzymatic subunit (SDHA-SDHB) in the matrix and the anchoring subunit (SDHC-SDHD) across the IMM. The enzymatic subunit exploits two electrons from succinate and passes them through a series of FeS clusters to the anchoring subunit where CoQ is reduced to CoQH$_2$. Different from cI, no proton is translocated for the reactions that occur in cII (Rütter et al., 2010). Electrons from both cI and cII are carried by CoQH$_2$ to enter the Q cycle processed by cIII. The catalytic activity of cIII depends on three redox-active subunits: cytochrome b (MT-CYB), the Rieske iron-sulfur [Fe2-S2] protein (UQCRCFS1), and cytochrome c1 (CYC1) (Yang and Tromppower, 1986). Electrons donated by CoQH$_2$ were transduced to cyt c via these three subunits sequentially. Each Q cycle generates two reduced cyt c and transports two protons (Crofts, 2004). The reduced cyt c then shuttles electrons to cIV, namely the cyt c oxidase (COX), whose catalytic core includes subunits 1, 2, and 3. Electrons are exploited from reduced cyt c at subunit 2 and reduce molecular oxygen to water at subunit 1. One proton is simultaneously translocated to IMS via subunit 3 upon each cyt c oxidation (Wilson and Prochaska, 1990). The oxidized cyt c then returns to its pool. In addition to working as an electron carrier, the oxidized cyt c also serves as a scavenger of reactive oxygen species (ROS) (Wang et al., 2003), a cardiolipin peroxidase (Kagan et al., 2005), and an apoptosis activator once released to the cytosol (Ow et al., 2008). The functions of cyt c beyond OXPHOS are discussed in the latter part of this review.

As the final step of OXPHOS, the proton gradient established by cI, cIII, and cIV drives cV to generate ATP. cV consists of two functional domains: F$_1$ and F$_0$. Protons passing through the F$_0$ domain across the IMM to the matrix release the energy provided by the proton electrochemical gradient. The F$_1$ domain at the matrix then uses the energy to charge cells by phosphorylating ADP to ATP (Jonckheere et al., 2012). Each ATP synthesis requires the translocation of 3 or 4 protons (Van Walraven et al., 1996; Guerra et al., 2002).

Dysfunction of ETC has been associated with various neurological diseases from infantile-onset neurodevelopmental regression (such as Leigh syndrome) to adult-onset optic neuropathy or peripheral neuropathy (such as Leber hereditary optic neuropathy (LHON) in cI deficiency, and neuropenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) in cV deficiency) (Gorman et al., 2016). Neurodegeneration diseases, especially PD, are also associated with ETC dysfunction. PD has been branded as a “cI disease” because of the discovery of MPP$^+$ (the metabolites of MPTP) which is a cI inhibitor (Nicklas et al., 1985; Ramsay et al., 1986). Rotenone, another commonly reported PD risk factor, is also a cI inhibitor (Betarbet et al., 2000). In post-mortem studies of PD patients, cI functional deficiency is found in substantia nigra or frontal cortex (Schapira et al., 1990; Parker et al., 2008). Similar cI deficiency is also found in non-brain tissues including platelets, skeletal muscles, or fibroblasts, indicating it is a systematic phenomenon (Parker et al., 1989; Wiedemann et al., 1999). Also, reports of cIII and cIV function in PD have been inconsistent (Mizuno et al., 1990; Wiedemann et al., 1999). Impairment of ETC causes excessive ROS, disruption of the electrochemical potential of the proton gradient, insufficient ATP production, and even cell death. Although it is widely observed that ETC functions are compromised in PD, genetic mutations of ETC proteins (either nuclear-encoded or mitochondrial-encoded) are rarely linked to PD. The discrepancy might suggest that the ETC dysfunction is secondary to other mechanisms that closely regulate mitochondria. In other words, ETC represents a hub where different PD-causing patho-mechanisms converge.

PD-Associated Genes and the ETC

To date, over 20 PD-related genes have been discovered. Although these familial PD cases are not common, and some may even have atypical features such as early onset (<50 years of age at onset) or early cognitive or psychiatric involvement, they provide great insights into the pathogenesis of PD. Many of the PD-causing genes affecting quality control systems of mitochondria, lysosomal regulation, or lipid/protein homeostasis, thus directly or indirectly influence ETC functions. In the following section, we will discuss the best-known genes and some newly identified
Li et al. Mitochondria ETC and Parkinson’s Disease

FIGURE 1 | The electron transport chain (ETC) consists of complexes I (cI) to V (cV), as well as two free electron carriers, CoQ and cyt c. NADH and FADH$_2$ donated electrons to cI and cII, respectively, causing reduction of CoQ into CoQH$_2$. The CoQH$_2$ is in turn oxidized by cIII where the electrons are delivered to cyt c. The reduced cyt c was then oxidized by cIV where the oxygen molecule was reduced as the terminal electron acceptor. Protons accumulated in the intermembrane space during oxidative phosphorylation via cI, cIII, and cIV, and are essential for cV to drive ATP synthesis. Some neurological diseases associated with mutations of cI-cV are listed.

ones with a focus on their influences on ETC (Figure 2 and Tables 1, 2).

PINK1 and PRKN: Key Players of Mitochondria Quality Control

Mutations in PRKN (previously known as PARK2, which encodes parkin) and PINK1 are the most common causes of early onset PD. PRKN mutants on 6q25.2-27 were found in 1998 (Kitada et al., 1998), and PINK1 mutants on 1p35-1p36 were identified in 2001–2002 (Valente et al., 2001, 2002, 2004). Mutations in the two genes have since been reported worldwide (Kilarski et al., 2012). Early onset PD associated with either gene showed similar clinical features, including slow disease progression, good levodopa response, lower limb dystonia, early psychiatric symptoms, and a higher likelihood of motor complications than idiopathic PD (Koros et al., 2017). Pathologically, Lewy bodies can be absent in patients with either PRKN or PINK1 mutations (Pouloupolou et al., 2012; Takanashi et al., 2016). These similarities reflect their common mechanism in PD pathogenesis.

It is now known that parkin, along with PINK1, is critical for mitochondria quality control through various pathways including mitophagy, formation of mitochondrial-derived vesicles, mitochondrial fission, and facilitation of mitochondrial biogenesis (Ge et al., 2020). When mitochondria are jeopardized, PINK1 is recruited to and stabilized on the OMM. The stabilized PINK1 then recruits and activates parkin, an E3 ligase that assembles ubiquitin chains on its substrates including OMM proteins which subsequently recruits ubiquitin-binding autophagy receptors and ultimately leads to autophagosome formation and lysosomal degradation. Other substrates of parkin include Mitofusin-1 and -2, whose proteolysis divert mitochondria from fusion into fission (Tanaka et al., 2010; Ziviani et al., 2010); parkin interacting substrate (PARIS, also known as ZNF746), whose degradation stimulates mitochondrial biogenesis (Shin et al., 2011; Lee et al., 2017); and also hnRNP F, a translation repressor that regulates the localized synthesis of nuclear-encoded mitochondrial proteins (including some ETC components) (Lee et al., 2017). In addition to PINK1-dependent phosphorylation, other post-translational modifications of parkin, such as S-nitrosylation, are also critical for the E3 ligase activity and solubility of parkin and have been comprehensively reviewed elsewhere (Chakraborty et al., 2017).

The integrity of ETC is highly correlated with the PINK1-Parkin-mediated quality control mechanisms. Fibroblasts or leukocytes with parkin loss-of-function mutations showed impaired cI activities (Müftüoglu et al., 2004; Mortiboys et al., 2008), and human fibroblasts or mouse embryonic fibroblasts of PINK1 mutants also showed cI dysfunction (Morais et al., 2009; Amo et al., 2014). The turnover rates of mitochondrial proteins could be an indicator of mitochondrial quality control. A study using fly heads showed that ETC mitochondrial proteins had a greater dependence on parkin or Pink1 than other non-ETC mitochondrial proteins. Nineteen of the ETC proteins had...
FIGURE 2 | Different pathomechanisms converge on mitochondria in Parkinson's disease. (A) PINK1 and parkin mediate mitochondrial quality control processes such as mitophagy. PINK1 is also required for phosphorylation of Ndufa10 to facilitate the reduction of ubiquinone by complex I. (B) Mutations in LRRK2 block mitophagy by preventing the degradation of Miro or by trapping Rab10 whose interaction with OPTN is pivotal for autophagy/mitophagy. (C) DJ-1 scavenges ROS through sequential oxidation at Cys106. The oxidized DJ-1 acts as a chaperone to facilitate the assembly and activities of cI, cIV, and cV. (D) Accumulation of GlcCer and other lipids in GCase mutants impairs lysosomal functions. Mutations in GCase reduces the expression of NMNAT2, resulting in a significant reduction of NAD+/NADH. (E) α-Syn monomers or oligomers interrupt the activities of cI and cV. The fibrilized α-Syn triggers Lewy body formation which sequestrates abundant mitochondria. (F) Deficits in iPLA2-β cause lipid imbalance that may interrupt ETC functions. (G) UQCRC1 is critical in cIII assembly and functions, and also prevents cyt c release. (H) CHCHD2 is a chaperone of cIV, activates COX4I2 and its own expression, complexes with MICS to prevent cyt c release, and regulates the cristae structure by stabilizing OPA1 and MICOS complex.

longer half-lives in parkin mutants than in autophagy-impaired Atg7 mutants, suggesting the turnover of these proteins may be achieved via an as selective manner. More than half belong to cI (10/19), while proteins from the other complexes are also affected (1 in cII, 2 in cIII, 3 in cIV, and 3 in cV) (Vincow et al., 2013). The predominance of cI proteins likely explains why cI dysfunction is invariably reported in PRKN or PINK1 mutants.

Activities of cI could also be regulated by PINK1 independent of parkin. An accessory subunit of cI, Ndufa10, is pivotal for the ubiquinone-reducing capacity of cI, and the phosphorylation of Ndufa10 requires PINK1 (Morais et al., 2014). Overexpression of Ndufa10 or expression of its phoshomimetics could reverse the defects in pink59-null mutant Drosophila, but not parkin mutants (Morais et al., 2014; Pogson et al., 2014). Ndufa10 phosphorylation also rescued the ROS-induced apoptosis in PINK1 knockout mouse fibroblasts (Morais et al., 2014), suggesting that PINK1 is anti-apoptotic. The anti-apoptotic effects of PINK1 are also attributed to the phosphorylation of the mitochondrial chaperone TRAP1 (also known as Hsp75) which prevents cyt c release from mitochondria (Pridgeon et al., 2007). In tumor cells, TRAP1, phosphorylated by ERK1/2 and Src, prohibited the generation of ROS by inhibiting cI and cIV, respectively (Masgras et al., 2017). Whether the phosphorylation of TRAP1 by PINK1 has any influence on ETC functions awaits further investigation.

**DJ-1: A Prominent Chaperone in Mitochondria**

**DJ-1** (also known as **PARK7**) mutations cause autosomal recessive, early onset PD. It was initially reported in 2003 from two genetically isolated consanguineous families (Bonifati et al., 2003), and has a frequency of about 0.4% in early onset PD, much lower than that of **PRKN** and **PINK1** (Kilarski et al., 2012).

DJ-1 is ubiquitously expressed (Mita et al., 2018) and serves a dual role as an oxidative sensor and also an antioxidant protein. Immunostaining of oxidized DJ-1 (oxDJ-1) revealed reactivity in SNc, striatum, and inferior olivary nucleus in postmortem brain of elders with Lewy body pathology. Co-localization of oxDJ-1 and α-synuclein (α-Syn) was also reported (Saito et al., 2014). The cysteine residue (C106) in its active site could be sequentially oxidized into the sulfenylated form (-SOH), sulfinated form (-SO2H), and sulfonic form (-SO3H) (Kinumi et al., 2004). The sulfonated form is the active form that not only prevents α-Syn fibrillation (Zhou et al., 2006) but also plays protective roles in promoting mitochondria fission and cell viability to rotenone (Blackinton et al., 2009). These results suggested that DJ-1 is an oxidative stress-dependent chaperone.
Since mitochondria are the major site of intracellular ROS production, it is intuitive that DJ-1 plays an important role in mitochondria physiology. The subcellular and submitochondrial fractionation of mouse brains shows that abundant endogenous DJ-1 is localized in mitochondria (Zhang et al., 2005). Depletion of DJ-1 significantly reduced the oxygen consumption rate, ATP production (Heo et al., 2012), and cI activity (Hayashi et al., 2009; Heo et al., 2011). Though previously under-reported, recent studies showed that PLA2G6 might contribute to early onset PD as frequently as 0.54–1.3%, more common than DJ-1 (Kumar et al., 2020; Zhao et al., 2020). Among them, DP and AREP are both characterized by adult-onset as well as levodopa-responsiveness, and are not reported until 2009 and 2011, respectively (Paisan-Ruiz et al., 2009; Shi et al., 2011). Though previously under-reported, recent studies showed that PLA2G6 might contribute to early onset PD as frequently as 0.54–1.3%, more common than DJ-1 (Kumar et al., 2020; Zhao et al., 2020).

PLA2G6 encodes a group VIA calcium-independent phospholipase A2β enzyme (iPLA2β), which is responsible for the selective hydrolysis of glycerophospholipids to generate fatty acids and lysophospholipids (Jenkins et al., 2006). In PLA2G6-knockout mice, granules containing collapsed mitochondria were observed in axons (Beck et al., 2011). In iPLA2-VIA (the homolog of PLA2G6) null Drosophila, aberrant mitochondria with reduced respiratory chain activities of cI and cII or ATP production were demonstrated (Kinghorn et al., 2015; Lin et al., 2018). These changes, however, are unlikely associated with changes in cardiolipin composition (Kinghorn et al., 2015), which is the main component of mitochondria inner membrane. Lin et al. showed that none of the glycerophospholipids significantly changed in iPLA2-VIA null Drosophila. Rather, they showed a decrease in ceramide phosphoethanolamines, and an increase in ceramides, dihydroceramides, and other sphingolipid intermediates (Lin et al., 2018). Some ceramides are associated with compromised respiratory chain activities, increased ROS production, impaired mitochondria membrane potential, mitophagy, and apoptosis (Kogot-Levin and Saada, 2014). By using liquid chromatography-tandem mass spectrometry (LC-MS/MS), it was revealed that subunit 2 of cIV might have allosteric interactions with C6-ceramide (Kota et al., 2012). Reduced cIV activities were found in the liver of ceramide

### TABLE 1 | PD-associated genes and their influences on each ETC complex.

| Gene | Mechanism | Complex I | Complex II | Complex III | Complex IV | Complex V | References |
|------|-----------|-----------|-----------|-------------|------------|-----------|------------|
| PRKN and PINK1 | Protein turnover | + | + | + | + | + | Vincow et al., 2013 |
| PINK1 | Translation derepression | + | + | + | + | + | Gehlke et al., 2015 |
| PARK7 | Phosphorylation | + | + | + | + | + | Morais et al., 2014 |
| PLA2G6 | Ceramide metabolism | + | + | + | + | + | Hayashi et al., 2009; Heo et al., 2012; Chen et al., 2019 |
| GBA | Unknown, probably regulating mitophagy, GlcCer metabolism, and NAD + production | + | + | + | + | + | Osellame et al., 2013; Schöndorf et al., 2018 |
| LRRK2 | Unknown, probably regulating mitophagy | + | + | + | + | + | Mortiboys et al., 2010 |
| SNCA | Mutant monomers or oligomers | + | + | + | + | + | Chinta et al., 2010; Reeves et al., 2015; Ludtmann et al., 2018 |
| CHCHD2 | Fibril-induced Lewy body formation | + | + | + | + | + | Aras et al., 2015; Meng et al., 2017 |
| UQORC1 | Chaperone | + | + | + | + | + | Aras et al., 2015 |
| UQORC1 | cIII core subunits | + | + | + | + | + | Unni et al., 2019; Lin et al., 2020 |

*+ + + indicates evidence of direct or indirect interactions but the exact involved subunits are still unclear.*

**PLA2G6: ETC Dysfunction and Lipid Imbalance**

PLA2G6-associated neurodegeneration (PLAN) consists of a series of rare diseases: infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (ANAD), dystonia-parkinsonism (DP), and autosomal recessive early onset parkinsonism (AREP).
TABLE 2 | Canonical OXPHOS functions of the mitochondrial complex subunits affected by PD-associated genes in Table 1.

| Complex | Subunits* | Functions | Associated PD genes |
|---------|-----------|-----------|---------------------|
| Complex I | NDUFB8 | An accessory subunit of the P module | PRKN, PINK1 |
| | NDUFS2 | A core subunit of the Q module | PRKN, PINK1 |
| | NDUFB11 | An accessory subunit of the P module | PRKN, PINK1 |
| | NDUF7 | An assembly subunit | PRKN, PINK1 |
| | NDUFV2 | A core subunit of N module | PRKN, PINK1 |
| | NDUFA5 | An accessory subunit of Q module | PRKN, PINK1 |
| | NDUFA9 | An accessory subunit of P module | PRKN, PINK1 |
| | NDUFA13 | An accessory subunit of P module | PRKN, PINK1 |
| | NDUFA8 | An accessory subunit of P module | PRKN, PINK1 |
| | NDUFB10 | An accessory subunit of P module | PRKN, PINK1, PARK7 |
| | NDUFA10 | An accessory subunit of P module | PARK7 |
| | ND1 | An accessory subunit of P module | PARK7 |
| Complex II | SDHB | An enzymatic subunit | PRKN, PINK1 |
| Complex III | UQCRB | Maintaining Cytochrome b stability with UQCRQ | PRKN, PINK1 |
| | UQCRBC | A core subunit of cII; in situ processing of UQCRF51 (probable) | PRKN, PINK1 |
| | UQRC1 | A core subunit of cII; in situ processing of UQCRF51 (probable) | - |
| | UQCRF51 | A core subunit of cII; responsible for transducing electrons from Cytochrome b to Cytochrome c-1 | UQCRQ |
| | CYC1 | To reduce cytochrome c | UQCRQ |
| | UQCRQ | Maintaining Cytochrome b stability with UQCRB | UQCRQ |
| | UOCR10 | Unclear | UQCRQ |
| | UOCR11 | Unclear | UQCRQ |
| Complex IV | COX5A | Response to hypoxia and regulate NO production | PRKN, PINK1 |
| | COX4I1 | Modulation of oxygen affinity | PRKN, PINK1, CHCHD2 |
| | COX2 | To oxidize cytochrome c | PRKN, PINK1 |
| | NDUF4A | CVI perishment | PARK7 |
| Complex V | ATP5L | A subunit of the F0 domain | PRKN, PINK1 |
| | ATP5HL1 | A subunit of the F0 domain | PRKN, PINK1 |
| | ATP5F1 | A subunit of the F0 domain | PRKN, PINK1 |
| | ATP5P1 | A subunit of the F0 domain | PRKN, PINK1 |
| | ATP5F1B | A subunit of the F1 domain | PARK7, SNCA |

*All designated by human gene names.

GBA1: Lysosomal Dysfunction Linking to ETC Impairment

GBA1 is not a traditional PARK-designated gene. Its biallelic mutations cause Gaucher’s disease, which is a lysosomal storage disease. However, increasing reports have identified GBA1 variants as common risk factors of PD (Lwin et al., 2004; Iwaki et al., 2019). The combined odds ratio of any GBA1 mutant in PD patients versus controls was as high as 5.43 (95% CI, 3.89 to 7.57) according to an international multi-center study, with the most common variants being N370S and L444P (Sidransky et al., 2009). PD patients with GBA1 variants have a more aggressive motor deterioration and accelerated course of dementia than other PD patients (Stoker et al., 2020).

GBA1 encodes β-glucocerebrosidase (GCase), a lysosomal enzyme hydrolyzing glucosylceramide (GlcCer) into glucose and ceramide. The enzyme activity of GCase decreases in mutation carriers and elder individuals (Rocha et al., 2015; Hallett et al., 2018). In contrast to the PLA2G6 mutants that cause accumulation of ceramide, GCase deficiency results in the accumulation of GlcCer, as well as alterations of glycosylsphingosine (GlcSph), sphingosine (Sph), sphingosine-1-phosphate (S1P) in different brain regions (Muñoz et al., 2021). GCase deficiency impaired lysosomal recycling (Magalhaes et al., 2016) and lysosomes enriched with GlcCer accelerates and stabilizes soluble α-Syn oligomers, which eventually become amyloid fibrils (Mazzulli et al., 2011). GCase deficiency also causes significant mitochondrial morphological changes, decreased oxygen consumption rate, and reduced respiratory chain complex activities (Osellame et al., 2013; Schöndorf et al., 2018).

The mechanism of how a lysosomal enzyme such as GCase influences ETC is elusive. In gba knockout mice inhibited activities of cI and cII-III, but not cIV, were observed. Reduced co-localization of mitochondrial marker with LC3 and parkin recruitment suggested impaired mitophagy which might explain the compromised ETC activities (Osellame et al., 2013). However, the mitophagy theory unlikely explains the discrepancy between cIV and other complexes (Gegg and Schapira, 2016). CoQ, which transfers electrons from cI and cII to cIII, has been shown beneficial for mitochondrial function in fibroblasts from patients of Gaucher disease (de la Mata et al., 2015), but definite evidence showing deficits of CoQ in GCase deleted cells is lacking.

The ETC dysfunction can also result from alterations of mitochondrial metabolism. In iPS cells derived from PD patients carrying GBA1 variants, cI perishment with decreased expression of nicotinamide mononucleotide adenyltransferased2 (NMNAT2) was found. Supplementation of NAD+ precursor nicotinamide riboside rescued mitochondrial defects and autophagy. The lipidomic analysis of mitochondria showed no accumulation of GlcCer in mitochondria except for G16-GlcCer (Schöndorf et al., 2018). Where do the G16-GlcCer exactly locate and whether it regulates ETC functions are still unanswered.
LRRK2: A Master Kinase Regulating the Mitochondrial Quality Control System

Mutations in LRRK2, which encodes the leucine-rich repeat kinase 2 (LRRK2), are the most prevalent causes of autosomal dominant PD worldwide. LRRK2-associated PD (LRRK2-PD) are characterized by late-onset (>60 years), with clinical features and treatment response resembling idiopathic PD (Tan et al., 2019; Lesage et al., 2020; Zhao et al., 2020). G2019S is the most common variant in Europe and North America, accounting for 4% of familial PD and 1% of sporadic PD (Healy et al., 2008), while in Asia this variant is rare but prominent allelic heterogeneity was observed (Foo et al., 2017, 2020). One of the main features of LRRK2-PD is its incomplete penetrance which varies among each variant and even different ethnicities (Trinh et al., 2014). A polygenic risk score has been developed to predict the vulnerability of G2019S carriers, and genes involving the vacuolar functions, lysosomal functions, and endocytic pathways were included (Nalls et al., 2019). Recent studies suggested that mitochondrial DNA damage is also a potential biomarker in LRRK2-PD (Gonzalez-Hunt et al., 2020). Reduced CI activities and increased mitochondria DNA copy number were observed in fibroblasts derived from G2019S PD patients than from carriers (Delcambre et al., 2020), implying mitochondria in association with the incomplete penetrance of the G2019S variant.

LRRK2 is an enzyme with both kinase and GTPase activities (Berwick et al., 2019). The kinase activity of LRRK2 is responsible for phosphorylation of a subset of Rab small GTPase (Steger et al., 2016), which are important for exocytosis of synaptic vesicles, and endolysosomal and Golgi apparatus protein sorting (Bae and Lee, 2020). Most PD-associated LRRK2 mutations represent gain-of-function alleles: the G2019S and I2020T in the kinase domain cause hyper-phosphorylation of Rab5 (West et al., 2005; Gloeckner et al., 2006), and R1441C/G/H in the Roc-COR domain increase kinase activities through disruption of the GTP hydrolysis activity (Weiss, 2008). Hyperphosphorylation of the Rabs disrupts their interaction with GT/GDP exchange factors (GEFs), and Rab GDP dissociation inhibitors (GDIs), resulting in their inactivation and membrane-cytosol redistribution (Steger et al., 2016).

Accumulating evidence has shown the impairment of mitochondria in LRRK2 mutants. Fibroblasts from LRRK2-PD patients exhibited defects including reduced mitochondria membrane potential, decreased ATP production, and decreased activities of complex I, II, and IV than healthy controls. Elongation of mitochondria and increased interconnectivity of mitochondria were also observed in LRRK2-PD fibroblasts (Mortiboys et al., 2010). LRRK2 is recruited to the mitochondrial outer membrane by mitochondria-anchored Rab29 (also called Rab7L1) (Gomez et al., 2019). RAB29 is also a risk gene of PD identified in PARK16 loci from several GWASs (Satake et al., 2009), and in addition to mitochondria Rab29 is also distributed at trans-Golgi network, lysosomes, and autophagic vesicles to regulate membrane trafficking, lysosome homeostasis, and axonal transport of autophagosomes with LRRK2 (Eguchi et al., 2018; Liu et al., 2018; Boecker et al., 2021). When gain-of-function LRRK2 mutants are anchored to mitochondria, it phosphorylates and traps Rab10 nearby (Gomez et al., 2019), causing decreased interaction of Rab10 with OPTN (optineurin), which is an autophagy receptor, therefore impairing mitophagy (Wauters et al., 2020). LRRK2 also regulates mitophagy through interaction with Miro, which anchors mitochondria to microtubules in mitochondria axonal transport (Hsieh et al., 2016). In mitophagy, PINK1/parkin-dependent phosphorylated Miro is targeted to proteasome degradation, thus “quarantining” damaged mitochondria from further transport (Wang et al., 2011). Upon CCCP treatment, Miro interacting with wild-type LRRK2 was degraded with time, while in the LRRK2 G2019S mutant, Miro showed decreased interaction with the mutant as well as resistance to degradation, delaying mitochondrial arrest and clearance in iPSC-derived neurons (Hsieh et al., 2016). In addition to mitophagy, LRRK2 is also involved in other mitochondrial quality control pathways like fusion and fission and its cytoskeleton dynamics and trafficking (Singh et al., 2019). Although evidence showing direct regulation of ETC by LRRK2 is limited, these quality control systems mentioned earlier do have profound impacts on ETCs. A recent in vitro study showed that PINK1-dependent phosphorylation of Ser111 of Rab8A antagonistically regulates the phosphorylation of Thr72 of Rab8A by LRRK2 (Vieweg et al., 2020), suggesting that there might be even closer crosstalk between the two master kinase.

SNCA: A Vicious Cycle of Proteinopathy and Mitochondriopathy

SNCA is the first identified gene associated with PD in 1997 (Polymeropoulos et al., 1997). While α-synuclein (α-Syn), which is encoded by SNCA, is one of the fundamental components in the Lewy body, patients with SNCA mutations (A30P, E46K, H50Q, G51D, A53E, and A53T) or multiplications are really rare, characterized by autosomal dominant inheritance, widely distributed age of onset (from 19 to 81 years), and more rapid cognitive impairment (Rosborough et al., 2017). Physiologically α-Syn is soluble in the cytosol, mainly located at presynaptic terminals to regulate the genesis, maintenance, and release of presynaptic vesicles (Kahle et al., 2000; Cabin et al., 2002; Burré et al., 2010). The α-synucleinopathy results from the imbalance among synthesis, aggregation, and clearance of α-Syn. As a result, aggregation of α-Syn takes place in the cytosol or around membranes. The conformations of the aggregates include oligomers, protofibrils, and fibrils (Lashuel et al., 2013). Accelerated oligomerization is the common trait among different disease mutants (Conway et al., 2000), and a higher propensity of fibrillation might correlate to the earlier onset age in A53T than A30P or E46K (Conway et al., 1998; de Oliveira and Silva, 2019). Post-translational modifications like phosphorylation at Ser129 and truncation at the carboxyl terminal are also pathogenic (Sato et al., 2011; Sorrentino and Giasson, 2020), while Ser87 is protective (Oueslati et al., 2012).

Both oligomers and fibrils (especially the amyloid fibrils) are toxic to mitochondria (Lashuel et al., 2013). Overexpression of α-Syn, cytosolic acidification, and Ser129 phosphorylated pathogenic α-Syn could all induce translocation of α-Syn to mitochondria (Cole et al., 2008; Shavali et al., 2008; Wang et al., 2019). By using a split-GFP tool, the translocated...
α-Syn was found distributed at the OMM and IMS but not in the matrix. Mutants (A30P and A53T) were more likely translocated to the IMS than the wild-type, and more α-Syn would be translocated to IMS upon oxidative stress or cI inhibition (Vicario et al., 2019). In turn, α-Syn inhibits cI activities in either monomer or oligomerized form (Chinta et al., 2010; Reeve et al., 2015; Ludtmann et al., 2018). Oligomeric α-Syn also selectively oxidized the ATP synthase β subunit and caused mitochondrial lipid peroxidation and increased mitochondrial permeability transition pore opening (Ludtmann et al., 2018). These suggest a vicious feed-forward loop between α-Syn aggregation and mitochondrial dysfunction.

Synergistic with oligomers, α-Syn fibrils impairs mitochondria by sequestering mitochondria and other organelles into Lewy bodies. Mahul-Mellier et al. (2020) added preformed fibrils (PFF) of α-Syn exogenously to the cultured neurons and found that at day 14 inclusions composed of loose fibrils start to interact with organelles, and at day 21 high enrichment of proteins from the mitochondria (including complexes I, II, and V), the endoplasmic reticulum, and the Golgi were detected in the Lewy body-like inclusions, corresponding to the reduction of the maximum OXPHOS capacity and maximum electron transport capacity at day 21. The important discovery links the two competitive but not conflicting theories of proteinopathy and mitochondriopathy in PD pathogenesis.

**UQRC1 and CHCHD2: Two Recently Found PD-Causing Genes Implicating Apoptotic Neuronal Death**

The association between CHCHD2 and autosomal dominant late-onset PD was discovered in four independent families through genome-wide linkage analysis (Funayama et al., 2015). CHCHD2 is a member of the coiled-coil-helix-coiled-helix (CHCH) domain-containing protein family known to participate in mitochondrial respiration, redox regulation, membrane ultrastructure, and dynamics in the IMS (Modjtahedi et al., 2016). CHCHD2 binds with cIV and regulates its activity. Under hypoxia, CHCHD2 activates the transcription of itself and COX4I2, which encodes cIV subunit-4 isoform 2 (COX IV-2) (Aras et al., 2015). The findings are compatible with the clinical data showing that fibroblasts derived from a patient with homozygous A71P mutant in CHCHD2 show reduced cIV activity in addition to cI deficiency (Lee et al., 2018). CHCHD2 is also important in maintaining the cristae structure and preventing apoptosis. Cristae are the home of ETC complexes and changes in the structure would alter the distribution of mitochondrial complexes, thus influencing the efficiency of OXPHOS (Gilkerson et al., 2003; Wilkens et al., 2013). In the flight muscles of CHCHD2 null Drosophila, the mitochondrial cristae structure was disorganized (Meng et al., 2017). Cristae integrity is regulated by OPA1 and the MICOS complex (Baker et al., 2019). In cells carrying PD-linked CHCHD2 mutations, the expression level of MICOS components, such as Mitofilin, MINOS1, CHCHD3, CHCHD6, were all reduced (Zhou et al., 2019). In Drosophila, Chchd2 knockout increases the degradation of OPA1 by peptidase YMEL (Liu W. et al., 2020). Similarly, OPA1 degradation is also observed in CHCHD2 and CHCHD10 double-knockout mice (Liu Y. T. et al., 2020). Mass spectrometry analysis reveals that CHCHD2 interacts with MICS1 (Meng et al., 2017), which is involved in cristae organization and cyt c stabilization, thereby prohibiting cells from apoptosis (Oka et al., 2008).

**UQRC1** is a newly identified PD-causing gene that is clinically characterized by autosomal dominant late-onset parkinsonism with polyneuropathy (Lin et al., 2019, 2020). UQRC1 encodes the mitochondrial ubiquinol-cyt c reductase core protein 1 (UQRC1), which is a core subunit of cIII. UQRC1 complexes with UQCRFS1 and interacts with UQCRFS1, CYC1, and other cIII subunits to regulate cIII activity (Sunitha et al., 2016; Unni et al., 2019). UQRC1 and UQRC2 are homologs to the mitochondrial-processing peptidase subunits and are predicted to process UQCRFS1 in situ during cIII assembly (Fernandez-Vizarra and Zeviani, 2018). However, in vivo experimental validation is required.

To date, only three UQRC1 human mutations have been identified and functionally validated: Y314S, I311L, and p.Ala25Glyfs*7. All three mutants show reduced maximal oxygen consumption rate, decreased ATP production, and increased ROS in SH-SY5Y cell lines. Drosophila and mice with the Y314S variant both showed degeneration of dopaminergic neurons and locomotor defects (Lin et al., 2020), providing direct evidence for the involvement of cIII in PD pathogenesis.

In addition to regulating cIII activities, UQRC1 is also anti-apoptotic. In cardiac cells, UQRC1 prevents ischemia/reperfusion injury by activating the PI3K/Akt/GSK-3β pathway, upregulating the anti-apoptotic protein Bcl-2, and downregulating the pro-apoptotic protein Bax (Yi et al., 2020). In Drosophila, our recent data reveal that uqcr-c1 associates with cyt c in mitochondria to gate its release (Hung et al., 2021). Previous reports have shown that complex I and II mediate signals for apoptosis (Lemarie and Grimm, 2011). Together, these findings suggest that the respiratory chain complexes are important regulators of apoptosis.

**THE MANY FACES OF ETC PROTEINS: FUNCTIONS BEYOND BIOENERGETICS AND POSSIBLE IMPLICATIONS IN NEURODEGENERATION**

Abundant studies have focused on mitochondrial quality control, lysosomal functions, apoptosis, and α-Syn aggregation in PD pathogenesis and their influences on ETC functions. In contrast, whether ETC proteins have any direct involvement in these pathways other than bioenergetics remains unclear in neurodegenerative diseases.

The roles of ETC proteins in apoptosis have been extensively studied in cancer cell biology. Both cI and cII are implicated as apoptotic sensors via different mechanisms. In cI, cleavage of NDUF51 by caspase-3 inhibits cI activities, causing ROS production and collapse of mitochondria membrane potential. The cleavage-resistant mutant NDUF51 D255A decreases ROS formation and delays the loss of plasma membrane integrity.
functions of cyt
from mitochondria.

(SET)/template-activating factor (TAF)-I
β
suppressor of variegation, enhancer of zeste and trithorax
et al., 2019b) but also by reducing the cyt
apoptotic not only by inhibiting caspase-3 activities (Kalpage
(Sanderson et al., 2013; Kalpage et al., 2019b), are both anti-
brain tissues and insulin-treated porcine tissues, respectively
we now know that cIII can keep cyt
at Ser47 and Tyr97 that are enriched in porcine
brain tissues and insulin-treated porcine tissues, respectively
(Sanderson et al., 2013; Kalpage et al., 2019b), are both anti-
-apoptotic not only by inhibiting caspase-3 activities (Kalpage
et al., 2019b) but also by reducing the cyt-β-COX interactions
to lower the COX reaction rate and ROS generation (Lee et al.,
2006; Guerra-Castellano et al., 2018; Kalpage et al., 2019b). It is
not known whether the post-translational modifications of cyt
alter any interactions with cIII. From the lessons of UQCRCl,
we now know that cIII can keep cyt from being released from
mitochondria.

Emerging evidence disclosed that there are other moonlight
functions of cyt. Abundant cyt was shown to translocate
to the nucleus prior to caspase activation in the cytosome
during the early phase of apoptosis (Nolin et al., 2016).
The translocated cyt hijacks histone chaperones such as
suppressor of variegation, enhancer of zeste and trithorax
(SET)/template-activating factor (TAF)-Iβ, inhibiting the
nucleosome assembly/disassembly activity and DNA repairing
(González-Arzola et al., 2015; Díaz-Moreno et al., 2018). DNA
damage is common in many neurodegenerative disorders,
including PD (Ainslie et al., 2021). Cyt can also be
identified as one of the components of brainstem Lewy bodies
(Wakabayashi et al., 2007) and might play a role as a trigger in
α-Syn aggregation (Hashimoto et al., 1999). α-Syn fibrils rather
than mutant oligomers or monomers specifically interact
with cyt according to an in vitro study (Leitão et al., 2021).
Whether similar aggregations could be replicated in vivo and
whether post-translational modifications of cyt as mentioned
earlier have any effects on these moonlight functions are
still unknown.

Some evidence showed that ETC proteins are also involved
in mitophagy or autophagy. For example, autophagy is inhibited
by the cII inhibitors Antimycin A or myxothiazol (Ma et al.,
2011). Another example is ECSIT (evolutionarily conserved
signaling intermediate in Toll pathways), which is essential in cI
formation (Vogel et al., 2007), found as a parkin substrate and
co-localized with LC3β in CCCP-treated macrophages (Carneiro
et al., 2018). Upon loss of ECSIT, parkin still accumulates on the
mitochondria, but the recruitment of LC3βII to mitochondria
is compromised. This suggested that parkin-induced ECSIT
ubiquitination is upstream of LC3βII recruitment for the
initiation of mitophagy (Carneiro et al., 2018). It is not clear
whether ECSIT participates in receptor-mediated mitophagy like
other mitochondrial outer membrane proteins such as FUNDC1,
NIX, and BNIP3. Further investigation is needed to elucidate
whether ECSIT mediates mitochondria clearance via a similar
mechanism in the nervous system.

**DISCUSSION**

In this review, we focus on the central role of ETC in
PD pathogenesis. We have discussed that ATP production
by mitochondria is directly or indirectly affected by reduced
turnover and altered post-translational modifications of ETC
proteins, impaired assembly or instability of mitochondrial
complexes, abnormal protein aggregation, and dysregulated lipid
metabolism. While mutations of ETC proteins are rarely linked
as a direct cause of PD (except for UQCRC1), impaired ETC
proteins may not only lead to excessive ROS production, but also
cause impeded mitophagy, α-Syn aggregation, and apoptosis in
PD pathogenesis.

It might be argued that for the long time scale of PD
progression, apoptosis is an acute cellular event that on the
surface does not perfectly explain the development of PD, but
when patients start to have detectable parkinsonism symptoms,
there is usually at least 40–60% dopaminergic neuronal loss
in the substantia nigra (Giguère et al., 2018), suggesting
progressive accumulation of neuronal loss. At the organismal
level, apoptosis of dopaminergic neurons occurs over time,
responding to stress such as aggregated proteins or ETC
dysfunction. At the cellular level, it takes time for a cell to reach
the threshold that breaks the balance between pro-apoptotic
and anti-apoptotic pathways. For example, ROS accumulation,
alterations of mitochondrial outer membrane permeability, and
the attenuation of antiapoptotic signals may fluctuate, and
mutant cells with the propensity of releasing cyt do not
mean that it releases cyt and activate caspases immediately.
This concept of ‘apoptotic threshold’ has been well illustrated
by a beautiful mathematical model (Rehm et al., 2006). In
fact, apoptosis has been implicated in many neurodegenerative
diseases, including PD (Moujalled et al., 2021). Although
it remains unclear whether loss of ETC function leads to
protein aggregation in vivo, apoptosis represents an important
pathogenic mechanism that warrants our attention.

In terms of mitochondrial dysfunction, the examples of
UQCRC1 and CHCHD2 have suggested that PD is not just a cI
disorder. Various genetic models of PD have now shown deficits
in cII to cV. The conventional belief of PD as a cI disorder might
be the result of publication bias or study limitations in earlier
studies. It has been shown that even in cI, the significance of the
deficiency could be influenced by the purity of the samples and
the assays we use (Parker et al., 2008). By using high-resolution
quantitative fluorescence immunohistochemistry, Reeve et al.
found that both cI and cIV were deficient in the remaining
dopaminergic synapses of idiopathic PD (Reeve et al., 2018). By

Ricci et al., 2004), suggesting cI inhibition as an accelerator
of apoptosis. A similar mechanism is found in granzyme
A-induced apoptosis, in which NDUF3 was cleaved (Martinvalet
et al., 2005). For cII, the acidification of matrix in response
to mitochondrial stress causes the disintegration of cII by
dissociating the anchoring subunit SDHC-SDHD from the
enzyme subunit SDHA-SDHB. As the SDHA-SDHB subunit
is still enzymatically active, it produces excessive ROS and
causes apoptosis. cII, therefore, is a pH sensor of the matrix in
programmed cell death.

The roles of complexes III and IV in apoptosis are less
clear, but the electron carrier between the two complexes, cyt-c,
has been known as a key player by activating apoptosis
protease activating factor-1 (Apaf-1) when released to the cytosol.
Post-translational modifications, especially phosphorylation, of
cyt-c have regulatory roles in both electron transport and
apoptosis (Kalpage et al., 2019a). Tissue-specific phosphorylation
of cyt-c at Ser47 and Tyr97 that are enriched in porcine
brain tissues and insulin-treated porcine tissues, respectively
(Sanderson et al., 2013; Kalpage et al., 2019b), are both anti-
apoptotic not only by inhibiting caspase-3 activities (Kalpage
et al., 2019b) but also by reducing the cyt-c-COX interactions
to lower the COX reaction rate and ROS generation (Lee et al.,
2006; Guerra-Castellano et al., 2018; Kalpage et al., 2019b). It is
not known whether the post-translational modifications of cyt-c
alter any interactions with cIII. From the lessons of UQCRCl,
we now know that cIII can keep cyt-c from being released from
mitochondria.

Emerging evidence disclosed that there are other moonlight
functions of cyt-c. Abundant cyt-c was shown to translocate
to the nucleus prior to caspase activation in the cytosome
during the early phase of apoptosis (Nolin et al., 2016).
The translocated cyt-c hijacks histone chaperones such as
suppressor of variegation, enhancer of zeste and trithorax
(SET)/template-activating factor (TAF)-Iβ, inhibiting the
nucleosome assembly/disassembly activity and DNA repairing
(González-Arzola et al., 2015; Díaz-Moreno et al., 2018). DNA
damage is common in many neurodegenerative disorders,
including PD (Ainslie et al., 2021). Cyt-c has also been
identified as one of the components of brainstem Lewy bodies
(Wakabayashi et al., 2007) and might play as a trigger in
α-Syn aggregation (Hashimoto et al., 1999). α-Syn fibrils rather
than mutant oligomers or monomers specifically interact
with cyt-c according to an in vitro study (Leitão et al., 2021).
Whether similar aggregations could be replicated in vivo and
whether post-translational modifications of cyt-c as mentioned
earlier have any effects on these moonlight functions are
still unknown.

Some evidence showed that ETC proteins are also involved
in mitophagy or autophagy. For example, autophagy is inhibited
by the cII inhibitors Antimycin A or myxothiazol (Ma et al.,
2011). Another example is ECSIT (evolutionarily conserved
signaling intermediate in Toll pathways), which is essential in cI
formation (Vogel et al., 2007), found as a parkin substrate and
co-localized with LC3β in CCCP-treated macrophages (Carneiro
et al., 2018). Upon loss of ECSIT, parkin still accumulates on the
mitochondria, but the recruitment of LC3βII to mitochondria
is compromised. This suggested that parkin-induced ECSIT
ubiquitination is upstream of LC3βII recruitment for the
initiation of mitophagy (Carneiro et al., 2018). It is not clear
whether ECSIT participates in receptor-mediated mitophagy like
other mitochondrial outer membrane proteins such as FUNDC1,
NIX, and BNIP3. Further investigation is needed to elucidate
whether ECSIT mediates mitochondria clearance via a similar
mechanism in the nervous system.
using imaging mass cytometry, a recent study revealed that there is even more widespread deficiency from complexes I to V in the postmortem human midbrain (Chen et al., 2021), contrary to the findings of earlier studies that were based on the measurements of biochemical activities only.

Mitochondrial therapies have been proposed as a potential treatment of PD (Thomas and Beal, 2010); however, many attempts have failed. The anti-diabetic drugs glitazones which improves mitochondrial functions (such as activities of complex I and complex II) and biogenesis (Bogacka et al., 2005; Ghosh et al., 2007) did lower the incidence of PD in retrospective cohort studies (Brauer et al., 2015; Brakedal et al., 2017), but failed to show benefits in modifying disease progression of early PD (NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, 2015). The randomized clinical trial of high dose CoQ did not slow disease progression (Beal et al., 2014). The limited bioavailability of CoQ has been considered as one of the main reasons for its failure (Bhagavan and Chopra, 2007). Longer follow-up or earlier administration of the drugs at prodromal stages may be necessary to reveal the potential benefits. Idebenone, a synthetic short-chain analog of CoQ with improved lipophilicity and bioavailability (Becker et al., 2010), having been approved as an orphan drug in treating LHON by European Medicines Agency (EMA) (European Medicines Agency [EMA], 2021) and Duscheenne muscular dystrophy by the United States Food and Drug Administration (FDA) (Pharmaceuticals, 2015), is tested in two PD clinical trials: (1) Idebenone Treatment of Early Parkinson's Disease symptoms (ITTP) (NCT03727295), and (2) A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD) (NCT04152655). The recruitment status of the former is due to end in May 2021, while the latter is still recruiting and is scheduled to complete by January 2023.

In conclusion, ETC dysfunction is a common feature in PD, secondary to various pathomechanisms. Increasing evidence has shown that complex I is not the only affected ETC complex. Other complexes, such as complex III and complex IV, are also involved. ETC dysfunction not only reduces ATP production but also induces apoptosis or impaired mitophagy that undermines neuronal viability in PD. So far there is still no silver bullet to prevent or to ameliorate PD progression. Nonetheless, new compounds or existing drugs await testing as potential therapeutic strategies for PD via improving ETC functions (Singh et al., 2021).

**AUTHOR CONTRIBUTIONS**

J-LL, T-YL, and C-CC: conceptualization. J-LL and T-YL: writing – original draft. C-CC: funding acquisition and supervision. All authors writing – review and editing.

**FUNDING**

This work was supported by grants from the Ministry of Science and Technology of Taiwan (MOST) (108-2311-B-002-011-MY3 and 110-2314-B-002-202) to C-CC.

**ACKNOWLEDGMENTS**

We thank the members of Chan Lab for critical comments on this manuscript.

**REFERENCES**

Aimsline, A., Huiting, W., Barazzuol, L., and Bergink, S. (2021). Genome instability and loss of protein homeostasis: converging paths to neurodegeneration? Open Biol. 11:200296. doi: 10.1098/rsob.200296

Alavian, K. N., Beutner, G., Lazrove, E., Sacchetti, S., Park, H. A., Licznerski, P., et al. (2014). An uncoupling channel within the c-subunit ring of the FIFOX ATP synthase is the mitochondrial permeability transition pore. *Proc. Natl. Acad. Sci. U.S.A.* 111, 10580–10585. doi: 10.1073/pnas.1401591111

Amo, T., Saiki, S., Sawayama, T., Sato, S., and Hattori, N. (2014). Detailed analysis of mitochondrial respiratory chain defects caused by loss of PINK1. *Neurosci. Lett.* 580, 37–40. doi: 10.1016/j.neulet.2014.07.045

Aras, S. Bai, M., Lee, I., Springett, R., Hüttemann, M., and Grossman, L. I. (2015). MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. *Mitochondrion* 20, 43–51. doi: 10.1016/j.mito.2014.10.003

Bae, J. E., and Lee, S. J. (2020). The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation. *Biochim. Biophys. Acta Mol. Basis Dis.* 1866:165632. doi: 10.1016/j.bbadis.2019.165632

Baker, N., Patel, J., and Khacho, M. (2019). Linking mitochondrial dynamics, cristae remodeling and supercomplex formation: how mitochondrial structure can regulate bioenergetics. *Mitochondrion* 49, 259–268. doi: 10.1016/j.mito.2019.06.003

Ball, N., Teo, W. P., Chandra, S., and Chapman, J. (2019). Parkinson’s disease and the environment. *Front. Neurrol.* 10:218. doi: 10.3389/fneur.2019.00218

Balsa, E., Marco, R., Perales-Clemente, E., Suklarczyk, R., Calvo, E., Landázuri, M. O., et al. (2012). NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. *Cell Metab.* 16, 378–386. doi: 10.1016/j.cmet.2012.07.015

Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., et al. (2014). A randomized clinical trial of high-dose coenzyme Q10 in early Parkinson disease: no evidence of benefit. *JAMA Neurol.* 71, 543–552. doi: 10.1001/jamaneurol.2014.131

Beck, G., Sugiyura, Y., Shinzawa, K., Kato, S., Setou, M., Tsujiimoto, Y., et al. (2011). Neuroaxonal dystrophy in calcium-independent phospholipase A2β deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. *J. Neurosci.* 31, 11411–11420. doi: 10.1523/jneurosci.0345-1111.2011

Becker, C., Bray-French, K., and Drewe, J. (2010). Pharmacokinetic evaluation of idebenone. *Expert Opin. Drug Metab. Toxicol.* 6, 1437–1444. doi: 10.1517/17425255.2010.530656

Berwick, D. C., Heaton, G. R., Azeggagh, S., and Harvey, K. (2019). LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. *Mol. Neurodegener.* 14:49. doi: 10.1186/s13024-019-0344-2

Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panah, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. *Nat. Neurosci.* 3, 1301–1306. doi: 10.1038/81834 Bhagavan, H. N., and Chopra, R. K. (2007). Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. *Mitochondrion* 7(Suppl.), S78–S88. doi: 10.1016/j.mito.2007.03.003

Blackjnton, J., Lakshminarasimhan, M., Thomas, K. J., Ahmad, R., Greggio, E., Raza, A. S., et al. (2009). Formation of a stabilized cysteine sulfenic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. *J. Biol. Chem.* 284, 6476–6485. doi: 10.1074/jbc.M806599200
Chen, C., McDonald, D., Blain, A., Sachdeva, A., Bone, L., Smith, A. L. M., et al. (2020). Mitochondrial mechanisms of LRRK2 G2019S penetrance. Front. Neurol. 11:881. doi: 10.3389/fneur.2020.00881
Diaz-Moreno, I., Velazquez-Cruz, A., Curran-French, S., Diaz-Quintana, A., and De la Rosa, M. A. (2018). Nuclear cytochrome c - a mitochondrial visitor regulating damaged chromatin dynamics. FEBS Lett. 592, 172–178. doi: 10.1002/1873-1649.12959
Dorsey, E. R., and Bloem, B. R. (2018). The Parkinson Pandemic-A call to action. JAMA Neurol. 75, 9–10. doi: 10.1001/jamanetwork.neurology.2017.3299
Eguchi, T., Kuwahara, T., Sakurai, M., Komori, T., Fujimoto, T., Ito, G., et al. (2018). LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc. Natl. Acad. Sci. U.S.A. 115, E9115–E9124. doi: 10.1073/pnas.1812196115
European Medicines Agency [EMA] (2021). EMEA/H/C/003834 - Summary of the European Public Assessment Report (EPAR) for Raxone. Available online at: https://www.ema.europa.eu/en/medicines/epar/raposnaxone (accessed September 6, 2021).
Fernandez-Vizarra, E., and Zeviani, M. (2018). Mitochondrial complex III Rieske Fe protein processing and assembly. Cell Cycle 17, 681–687. doi: 10.1080/15384101.2017.1417707
Foo, J. N., Chew, E. G. Y., Chung, S. J., Peng, R., Blauwendaart, C., Nalls, M. A., et al. (2020). Identification of risk loci for Parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study. JAMA Neurol. 77, 746–754. doi: 10.1001/jamaneurol.2020.0428
Foo, J. N., Tan, L. C., Irwan, I. D., Au, W. L., Low, H. Q., Prakash, K. M., et al. (2017). Genome-wide association study of Parkinson’s disease in East Asians. Hum. Mol. Genet. 26, 226–232. doi: 10.1093/hmg/ddw379
Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., et al. (2015). CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: a genome-wide linkage and sequencing study. Lancet Neurol. 14, 274–282. doi: 10.1016/S1474-4422(14)70266-2
GBD 2016 Parkinson’s Disease Collaborators (2018). Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939–953. doi: 10.1016/S1474-4422(18)30295-3
Ge, P., Dawson, V. L., and Dawson, T. M. (2020). PINK1 andParkinson mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease. Mol. Neurodegener. 15, 20. doi: 10.1186/s13075-020-00367-7
Gegg, M. E., and Schapira, A. H. (2016). Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol. Dis. 90, 43–50. doi: 10.1016/j.nbd.2015.09.006
Gehrke, S., Wu, Z., Klinkenberg, M., Sun, Y., Auburger, G., Guo, S., et al. (2015). PINK1 andParkinson control localized translation of respiratory chain component mRNAs on mitochondria outer membrane. Cell Metab. 21, 95–108. doi: 10.1016/j.cmet.2014.12.007
Ghosh, S., Patel, N., Rahn, D., McAllister, J., Sadeghi, S., Horwitz, G., et al. (2007). The thiazoildinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol. Pharmacol. 71, 1695–1702. doi: 10.1124/mol.106.033845
Giachin, G., Bouvertor, R., Acajousi, S., Pantalone, S., and Soler-López, M. (2016). Dynamics of human mitochondrial complex I assembly: implications for neurodegenerative diseases. Front. Mol. Biosci. 3:43. doi: 10.3389/fmbio.2016.00043
Giguère, N., Burke Nanni, S., and Trudeau, L. E. (2018). On cell loss and selective vulnerability of neuronal populations in Parkinson’s disease. Front. Neurol. 9:389. doi: 10.3389/fneur.2018.00389
Gillker, R. W., Setler, J. M., and Capaldi, R. A. (2003). The cristal membrane of mitochondria is the principal site of oxidative phosphorylation. FEBS Lett. 546, 355–358. doi: 10.1016/S0014-5793(03)00633-1
Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O’Neill, E., Meitinger, T., et al. (2020). The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223–232. doi: 10.1093/hmg/dd439
Glover, V., Gibb, C., and Sandler, M. (1986). The role of MAO in MPTP toxicity-a review. J. Neurochem. Suppl. 20, 65–76.
Gomez, R. C., Wawro, P., Lin, P., Alessi, D. R., and Pfeffer, S. R. (2019). Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases. J. Cell Biol. 218, 4157–4170. doi: 10.1083/jcb.20192184
González-Arzola, K., Díaz-Moreno, I., Cano-González, A., Díaz-Quintana, A., Velázquez-Campoy, A., Moreno-Beltrán, B., et al. (2015). Structural basis for inhibition of the histone chaperone activity of SET/TAF-I by cytochrome c. Proc. Natl. Acad. Sci. U.S.A. 112, 9908–9913. doi: 10.1073/pnas.1508040112

Gonzalez-Hunt, C. P., Thacker, E. A., Toste, C. M., Boulard, S., Deprets, S., Dubois, L., et al. (2020). Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease. Cell. Rep. 30, 363–367. doi: 10.1016/j.celrep.2020.02.028

Gorman, G. S., Chinnery, P. F., DiMauro, S., Hirano, M., McFarland, R., et al. (2016). Mitochondrial diseases. Nat. Rev. Dis. Primers 2:16080. doi: 10.1038/nrdp.2016.80

Gudz, T. I., Tserg, K. Y., and Hoppel, C. L. (1997). Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J. Biol. Chem. 272, 24154–24156. doi: 10.1074/jbc.272.39.24154

Guerra, G., Martinez, F., and Pardo, J. P. (2002). On the H+2e− stoichiometry of the respiratory chain. Biochem. Mol. Biol. Educ. 30, 363–367. doi: 10.1016/bm.2002.09.00133

Guerra-Castellano, A., Díaz-Quintana, A., Pérez-Mejías, G., Elena-Real, C. A., González-Arzola, K., García-Mauriño, S. M., et al. (2018). Oxidative stress is tightly regulated by cytochrome c phosphorylation and respirasome factors in mitochondria. Proc. Natl. Acad. Sci. U.S.A. 115, 7955–7960. doi: 10.1073/pnas.1806331115

Hallett, P., J., Huebecker, M., Brekk, O. R., Moloney, E. B., Rocha, E. M., Priestman, J. C., et al. (2019). Genetic risk of Parkinson disease and progression:: an exome wide-association study. Proc. Natl. Acad. Sci. U.S.A. 116, 9908–9913. doi: 10.1073/pnas.1508040112

Heo, J. Y., Park, J. H., Kim, S. J., Seo, K. S., Han, J. S., Lee, S. H., et al. (2012). DJ-1 protein is a membrane tether for cytochrome c oxidase and caspase-3 activity. FASEB J. 33, 1350–13514. doi: 10.1096/fj.20101120R

Kilarski, L. L., Pearson, J. P., Newsway, V., Majounie, E., Knipe, M. D., Misbahuddin, a.l., et al. (2012). Systematic review and UK-based study of PARK2 (parkin). PLoS Pathog. 8, e1002478. doi: 10.1016/j.celrep.2016.12.090

Kinghorn, K. J., Castillo-Quan, J. L., Bartolome, F., Angelova, P. R., Li, L., Pope, S., et al. (2015). Loss of PLAC2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 138(PT 7), 1801–1816. doi: 10.1093/brain/awv132

Kinumi, T., Kimata, J., Taira, T., Ariga, H., and Niki, E. (2004). Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 317, 722–728. doi: 10.1016/j.bbrc.2004.03.110

Koros, C., Simitis, A., and Stefanis, L. (2017). Genetics of Parkinson’s disease: genotype-phenotype correlations. Int. Rev. Neurobiol. 132, 197–231. doi: 10.1016/bs.irn.2017.01.009

Kota, V., Szulc, Z. M., and Hama, H. (2012). Identification of C(6)-ceramide-interacting proteins in D6P2T Schwann cells. Proteomics 12, 2179–2184. doi: 10.1002/pmc.20110527

Kumar, S., Yadav, N., Pandey, S., Muthane, U. R., Govindappa, S. T., Abbass, M. M., et al. (2020). Novel and reported variants in Parkinson’s disease genes confer high disease burden among Indians. Parkinsonism Relat. Disord. 78, 46–52. doi: 10.1016/j.parkreldis.2020.07.014

Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980. doi: 10.1126/science.6823561

Lashuel, H. A., Overk, C. R., Oueslati, A., and Masliah, E. (2013). The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48. doi: 10.1038/nrn3406

Lee, I., Salomon, A. B., Yu, K., Doan, J. W., Grossman, L. L., and Hüttemann, M. (2006). New prospects for an old enzyme: mammalian cytochrome c is tyrosine-phosphorylated in vivo. Biochemistry 45, 9121–9128. doi: 10.1021/bc06585v

Lee, R. G., Sedghi, M., Salari, M., Shearwood, A. J., Stentenbach, M., Kariminejad, A., et al. (2018). Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction. NeuroL. Genet. 4:e276. doi: 10.1212/nxg.000000000000276

Lee, Y., Stevens, D. A., Kang, S. U., Jiang, H., Lee, Y. L., Ko, H. S., et al. (2017). PINK1 primes parkin-mediated ubiquitination of PARIS in dopaminergic neuronal survival. Cell Rep. 18, 918–932. doi: 10.1016/j.celrep.2016.12.090

Leitão, A. D. G., Rudolphi-Soto, P., Chappard, A., Bhumakar, A., Lao, D., Hunter, D. J. B., et al. (2021). Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein. Commun. Biol. 4:1124. doi: 10.1038/s42003-021-02624-x

Lemarie, A., and Grimm, S. (2011). Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer? Oncogene 30, 3985–4003. doi: 10.1038/onc.2011.167

Lesage, S., Houot, M., Mangone, G., Tesson, C., Bertrand, H., Forlani, S., et al. (2020). Genetic and phenotypic basis of autosomal dominant Parkinson’s disease in a large multi-center cohort. Front. NeuroL 11, 682. doi: 10.3389/fneur.2020.00682

Levitt, P., Pintar, J. E., and Breakefield, X. O. (1982). Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic

Frontiers in Molecular Neuroscience | www.frontiersin.org 12 December 2021 | Volume 14 | Article 797833

Li et al.
neurons. Proc. Natl. Acad. Sci. U.S.A. 79, 6385–6389. doi: 10.1073/pnas.79.20.6385
Lin, C. H., Chen, P. L., Tai, C. H., Lin, H. I., Chen, C. S., Chen, M. L., et al. (2019). A clinical and genetic study of early-onset and familial parkinsonism in taiwan: an integrated approach combining gene dosage analysis and next-generation sequencing. Mov. Disord. 34, 506–515. doi: 10.1002/mds.27633
Lin, C. H., Tsai, P. I., Lin, H. Y., Hattori, N., Funayama, M., Jeon, B., et al. (2020). Mitochondrial UQCRCL1 mutations cause autosomal dominant parkinsonism with polyneuropathy. Brain 143, 3352–3373. doi: 10.1093/brain/awaa279
Lin, G., Lee, P. T., Chen, K., Mao, D., Tan, K. L., Zuo, Z., et al. (2018). Phospholipase PLABG6, a Parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to α-Synuclein gain. Cell Metab. 28, 605.e606–618.e606. doi: 10.1016/j.cmet.2018.05.019
Liu, W., Duan, X., Xu, L., Shang, W., Zhao, J., Wang, L., et al. (2020). CHCHD2 regulates mitochondrial morphology by modulating the levels of Opal1. Cell Death Differ. 27, 2014–2029. doi: 10.1038/s41418-019-0482-7
Liu, Y. T., Huang, X., Nguyen, D., Shammas, M. K., Wu, B. P., Dombi, E., et al. (2020). Loss of CHCHD2 and CHCHD10 activates OMA1 peptidase to disrupt mitochondrial cristae phopocopying patient mutations. Hum. Mol. Genet. 29, 1547–1567. doi: 10.1093/hmg/ddaa077
Liu, Z., Bryant, N., Kumaran, R., Belina, A., Abeliovich, A., Cookson, M. R., et al. (2018). LRRK2 phosphorylates membrane-bound Rab5 and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum. Mol. Genet. 27, 385–395. doi: 10.1093/hmg/ddx310
Ludmilla, M. H. R., Angelova, P. R., Horrocks, M. H., Choi, M. L., Rodrigues, M., Baev, A. Y., et al. (2018). α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease. Nat. Commun. 9:2293. doi: 10.1038/s41467-018-04422-2
Lwin, A., Orvicsky, E., Goker-Alpan, O., LaMarca, M. E., and Sidransky, E. (2004). Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81, 70–73. doi: 10.1016/j.ymgme.2003.11.004
Ma, X., Jin, M., Cai, Y., Xia, H., Long, K., Liu, J., et al. (2011). Mitochondrial electron transport chain complex III is required for antityman A to inhibit autophagy. Chem. Biol. 18, 1474–1481. doi: 10.1016/j.chembiol.2011.08.009
Magalhaes, J., Gegg, M. E., Migdalska-Richards, A., Doherty, M. K., Whitfield, P. D., and Schapira, A. H. (2016). Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum. Mol. Genet. 25, 3432–3445. doi: 10.1093/hmg/ddw185
Mahl-Melller, A. L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., et al. (2020). The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 117, 4971–4982. doi: 10.1073/pnas.1913904117
Martinvalet, D., Zhu, P., and Lieberman, J. (2005). PINK1 loss-of-function mutations affect mitochondrial complex I activity and deficient synaptic function. EMBO Mol. Med. 1, 99–111. doi: 10.1002/emmm.200900006
Mortiboys, H., Johansen, K. K., Aslly, J. O., and Bandmann, O. (2010). Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75, 2017–2020. doi: 10.1212/WNL.0b013e3181f9685
Mortiboys, H., Thomas, K. J., Koopman, W. J., Klaffke, S., Abou-Sleiman, P., Ophm, S., et al. (2008). Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Annu. Neurol. 64, 555–565. doi: 10.1002/ana.21492
Moujalled, D., Strasser, A., and Liddell, J. R. (2021). Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 28, 2029–2044. doi: 10.1038/s41418-021-00814-y
Muñoz, S. S., Petersen, D., Marlet, F. R., Kücükköse, E., and Galvagnion, C. (2021). The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson's disease. Biophys. Chem. 273:106534. doi: 10.1016/j.bpc.2020.106534
Nalls, M. A., Blauwendraat, C., Vallega, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., et al. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102. doi: 10.1016/s1474-4429(19)30326-5
Nicklas, W. J., Vyas, I., and Heikkilä, R. E. (1985). Inhibition of NADE-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503–2508. doi: 10.1016/0024-3205(85)90146-8
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators (2015). Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795–803. doi: 10.1016/s1474-4422(15)00144-1
Nolin, P., Michel, J., Wortham, L., Tchelidze, P., Banchet, V., Lalun, N., et al. (2016). Stage-Specific changes in the water, Na+, K+ contents of organelles during apoptosis, demonstrated by a targeted cryo correlative analytical approach. PLoS One 11:e0148727. doi: 10.1371/journal.pone.0148727
Oká, T., Sayano, T., Tamai, S., Yokota, S., Kato, H., Fujii, G., et al. (2008). Identification of a novel protein MICS1 that is involved in maintenance of mitochondrial morpho and apoptotic release of cytochrome c. Mol. Biol. Cell 19, 2597–2608. doi: 10.1091/mbc.e07-12-1205
Osellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Londt, A., Brandner, S., et al. (2013). Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson's disease. Cell Metab. 17, 941–953. doi: 10.1016/j.cmet.2013.04.014
Oueslati, A., Paleologou, K. E., Schneider, B. L., Aebischer, P., and Lashuel, H. A. (2012). Mimicking phosphorylation at serine 87 inhibits the aggregation and cellular toxicity of α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci. 32, 1536–1544. doi: 10.1523/jneurosci.3784-11.2012
Ow, Y. P., Green, D. R., Hao, Z., and Mak, T. W. (2008). Cytochrome c: functions beyond respiration. Nat. Rev. Mol. Cell Biol. 9, 532–542. doi: 10.1038/nrm2343
Paisan-Ruiz, C., Bhatia, K. P., Li, A., Hernandez, D., Davis, M., Wood, N. W., et al. (2009). Characterization of PLABG6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65, 19–23. doi: 10.1002/ana.21415
Parker, W. D. Jr., Boyson, S. J., and Parks, J. K. (1989). Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719–723. doi: 10.1002/ana.410260606
Rutter, J., Winge, D. R., and Schiffman, J. D. (2010). Succinate dehydrogenase -

Sanderson, T. H., Mahapatra, G., Pecina, P., Ji, Q., Yu, K., Sinkler, C., et al. (2014). The complex I subunit NDUF10 selectively rescues Drosophila pink1 mutants through a mechanism independent of mitochondy. PLoS Genet. 10(10). doi: 10.1371/journal.pgen.1004815

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Deheja, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047. doi: 10.1126/science.276.5321.2045

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., et al. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601. doi: 10.1002/mds.26424

Poulopoulos, M., Levy, O. A., and Alcalay, R. N. (2012). The neuropathology of genetic Parkin’s disease. Mov. Disord. 27, 831–842. doi: 10.1002/mds.24962

Pridgeon, J. W., Olzmann, J. A., Chin, L. S., and Li, L. (2007). PINK1 protects nigra neurons in Parkinson’s disease. NPJ Parkinson Dis. 3:9. doi: 10.1038/s41531-018-0044-6

Reeve, A. K., Grady, J. P., Cosgrave, E. M., Bennison, E., Chen, C., Hepplewhite, R. R., Salach, J. I., Dadgar, J., and Singer, T. P. (1986). Inhibition of the electron transport chain. J. Neurochem. 54, 823–827. doi: 10.1111/j.1471-4159.1990.tb03252.x

Schönfliess, J. D., Ivanayk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., et al. (2018). The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease. Cell Rep. 23, 2976–2988. doi: 10.1016/j.celrep.2018.05.009

Shavali, S., Brown-Borg, H. M., Ebadi, M., and Porter, J. (2008). Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci. Lett. 439, 125–128. doi: 10.1016/j.neulet.2008.05.005

Shi, C. H., Tang, B. S., Wang, L., Lv, Z. Y., Wang, J., Luo, L. Z., et al. (2011). PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. Neurology 77, 75–81. doi: 10.1212/WNL.0b013e31821cadc3

Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. L., Pletnikova, O., et al. (2011). PARIS (PF746) repressing of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 144, 689–702. doi: 10.1016/j.cell.2011.02.010

Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 361, 1651–1661. doi: 10.1056/NEJMoa0912091

Singh, A., Faccenda, D., and Campanella, M. (2021). Pharmacological advances in mitochondrial therapy. EBioMedicine 65:103244. doi: 10.1016/j.ebiomed.2021.103244

Singh, A., Zhi, L., and Zhang, H. (2019). LRRK2 and mitochondria: recent advances and current views. Brain Res. 1702, 96–104. doi: 10.1016/j.braine.2018.06.010

Sorrentino, Z. A., and Giasson, B. I. (2020). The emerging role of α-synuclein truncation in aggregation and disease. J. Biol. Chem. 295, 10224–10244. doi: 10.1074/jbc.REV120.011743

Steeger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., et al. (2016). Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5:e12813. doi: 10.7554/eLife.12813

Stoker, T. B., Camacho, M., Winder-Rhodes, S., Liu, G., Scherer, C. R., Folkitt, T., et al. (2020). Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 91, 695–702. doi: 10.1136/jnnp-2020-322857

Sunitha, B., Gayathri, N., Kumar, M., Khesara Prasad, T. S., Nalini, A., Padmanabhan, B., et al. (2016). Muscle biopsies from human muscle diseases with myopathic pathology reveal common alterations in mitochondrial function. J. Neurochem. 138, 174–191. doi: 10.1111/jnc.13626

Takasahi, M., Li, Y., and Hattori, N. (2016). Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 86, 2212–2213. doi: 10.1212/wnl.0000000000002744

Tan, M. M. X., Malek, N. A., Hubbard, L., Pittman, A. M., Joseph, T., et al. (2019). Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study. Brain 142, 2828–2844. doi: 10.1093/brain/awv191

Tanaka, A., Cleland, M. M., Xu, S., Narendra, D. P., Suen, D. F., Karbowski, M., et al. (2010). Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J. Cell Biol. 191, 1367–1380. doi: 10.1083/jcb.201007013

Thomas, B., and Beal, M. F. (2010). Mitochondrial therapies for Parkinson’s disease. Mov. Disord. 25(Suppl. 1), S155–S160. doi: 10.1002/mds.22781

Trinh, J., Guella, I., and Farrer, M. J. (2014). Disease penetrance of late-onset parkinsonism: a meta-analysis. IAMA Neurology 71, 1535–1539. doi: 10.1001/jamaneurology.2014.1909

Unni, S., Thiyyagarajan, S., Srinivas Bharrath, M. M., and Padmanabhan, B. (2019). Tryptophan oxidation in the UQCRC1 subunit of mitochondrial complex III (Uqcrbc) in a mouse model of myopathygenesis caused large structural changes in the complex: a molecular dynamics simulation study. Sci. Rep. 9:10694. doi: 10.1038/s41598-019-4708-6

Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160. doi: 10.1126/science.1096284

Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., et al. (2001). Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68, 895–900. doi: 10.1086/319522

Valente, E. M., Brancati, F., Ferraris, A., Graham, E. A., Davis, M. B., Breteler, M. M., et al. (2002). PARK6-linked parkinsonism occurs in several European families. Ann. Neurol. 51, 14–18. 
Van Wailer, H. S., Strotmann, H., Schwarz, O., and Rumberg, B. (1996). The H+/ATP coupling ratio of the ATP synthase from thiol-modulated chloroplasts and two cyanobacterial strains is four. FEBS Lett. 379, 309–313. doi: 10.1016/0014-5793(95)01536-1

Vicario, M., Cieri, D., Valles, F., Catoni, C., Barazzuol, L., Berto, P., et al. (2019). A split-GFP tool reveals differences in the sub-mitochondrial distribution of wt and mutant alpha-synuclein. Cell Death Dis. 10:857. doi: 10.1038/s41419-019-2092-1

Vieugé, S., Mulholland, K., Bräuning, B., Kachariya, N., Lai, Y. C., Toth, R., et al. (2020). PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72. Biochem. J. 477, 1651–1668. doi: 10.1042/ bjci20190664

Vincow, E. S., Merrihew, G., Thomas, R. E., Shulman, R. P., MacCoss, M. J., et al. (2013). The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc. Natl. Acad. Sci. U.S.A. 110, 6400–6405. doi: 10.1073/pnas.1211132110

Vogel, R. O., Janssen, R. J., van den Brand, M. A., Dieteren, C. E., Verkaart, S., Vieweg, S., Mulholland, K., Bräuning, B., Kachariya, N., Lai, Y. C., Toth, R., et al. (2020). The role of genetics and two cyanobacterial strains is four. Frontiers in Molecular Neuroscience | www.frontiersin.org

Wang, Z. B., Li, M., Zhao, Y., and Xu, J. X. (2003). Cytochrome C is a hydrogen peroxide scavenger in mitochondria. FEBS Lett. 554, 219–224. doi: 10.1016/S0014-5793(03)00735-4

Wang, X., Becker, K., Levine, N., Zhang, M., Lieberman, A. P., Moore, D. J., et al. (2019). Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathol. Commun. 7:41. doi: 10.1186/s40478-019-0696-4

Wang, X., Winter, D., Ashrafi, G., Schlefe, J., Wong, Y. L., Selkoe, D., et al. (2011). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147, 893–906. doi: 10.1016/j.cell.2011.10.018

Wang, Z. B., Li, M., Zhao, Y., and Xu, J. X. (2003). Cytochrome C is a hydrogen peroxide scavenger in mitochondria. Protein Pept. Lett. 10, 247–253. doi: 10.2174/092986603779013

Wauters, F., Cornelissen, T., Imberechts, D., Martin, S., Koenijoro, B., Sue, C., et al. (2020). LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy 16, 203–222. doi: 10.1080/15548627.2019.1603548

Weiss, B. (2008). ROCO kinase activity is controlled by internal GTPase function. Sci. Signal. 1:x27. doi: 10.1126/scisignal.312p27

West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. M., Ross, C. A., et al. (2005). Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842–16847. doi: 10.1073/pnas.0507360102

Wiedemann, F. R., Winkler, K., Lins, H., Wallesch, C. W., and Kunz, W. S. (1999). Detection of respiratory chain defects in cultivated skin fibroblasts and skeletal muscle of patients with Parkinson’s disease. Ann. N. Y. Acad. Sci. 983, 426–429. doi: 10.1111/j.1749-6632.1999.tb07870.x

Wilkins, V., Kohl, W., and Busch, K. (2013). Restricted diffusion of OXPHOS complexes in dynamic mitochondria delays their exchange between cristae and engenders a transitory mosaic distribution. J. Cell Sci. 126( Pt 1), 103–116. doi: 10.1242/jcs.108852

Wilson, K. S., and Prochaska, L. J. (1990). Phospholipid vesicles containing bovine heart mitochondrial cytochrome c oxidase and subunit III-deficient enzyme: analysis of respiratory control and proton translocating activities. Arch. Biochem. Biophys. 282, 413–420. doi: 10.1016/0003-9861(90)90137-n

Yang, X. H., and Trumpower, B. L. (1986). Purification of a three-subunit ubiquinol-cytochrome c oxidoreductase complex from Paracoccus denitrificans. J. Biol. Chem. 261, 12282–12289.

Yi, T., Wu, X., and Li, H. (2020). Ubiquinol-cytochrome c reductase core protein 1 overexpression protects H9c2 cardiac cells against mimic ischemia/reperfusion injury through PI3K/Akt/GSK-3β pathway. Biochem. Biophys. Res. Commun. 529, 904–909. doi: 10.1016/j.bbrc.2020.06.089

Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S. W., Marupudi, N. I., et al. (2005). Mitochondrial localization of the Parkinson’s disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14, 2063–2073. doi: 10.1093/hmg/ddl211

Zhao, R. Z., Jiang, S., Zhang, L., and Yu, Z. B. (2019). Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int. J. Mol. Med. 44, 3–15. doi: 10.3892/ijmm.2019.4188

Zhao, Y., Qin, L., Pan, H., Liu, Z., Jiang, L., He, Y., et al. (2020). The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population. Brain 143, 2220–2234. doi: 10.1093/brain/awaa167

Zhou, W., Ma, D., Sun, A. X., Tran, H. D., Ma, D. L., Singh, B. K., et al. (2019). PD-linked CHCHD2 mutations impair CHCHD10 and MICO complex leading to mitochondria dysfunction. Hum. Mol. Genet. 28, 1100–1116. doi: 10.1093/hmg/ddy413

Zhou, W., Zhu, M., Wilson, M. A., Petsko, G. A., and Fink, A. L. (2006). The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol. 356, 1036–1048. doi: 10.1016/j.jmb.2005.12.030

Zigdon, H., Kogot-Levin, A., Park, J. W., Goldschmidt, R., Kelly, S., Merrill, A. H. Jr., et al. (2013). Ablation of ceramide synthase 2 causes chronic oxidative stress due to disruption of the mitochondrial respiratory chain. J. Biol. Chem. 288, 4947–4956. doi: 10.1074/jbc.M112.402719

Ziviani, E., Tao, R. N., and Whitworth, A. J. (2010). Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl. Acad. Sci. U.S.A. 107, 5018–5023. doi: 10.1073/pnas.0913485107

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Lin, Chen, Guo, Huang, Chen, Lin and Chan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.